Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Delmopinol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delmopinol SCHEMBL20299535 | 1.00 | PDK1 (0.33) | PDK1TSHRPDK2PDK3 | |
| Delmopinol SCHEMBL20298306 | 0.99 | PDK1 (0.33) | PDK1PDK2PDK3 | |
| Delmopinol SCHEMBL120704 | 0.99 | PDK1 (0.33) | PDK1PDK2PDK3 | |
| Delmopinol SCHEMBL9614970 | 0.97 | PDK1 (0.31) | PDK1TSHR | |
| Delmopinol SCHEMBL23705764 | 0.97 | PDK1 (0.33) | PDK1PDK2PDK3 | |
| Delmopinol SCHEMBL23705768 | 0.97 | PDK1 (0.33) | PDK1PDK2PDK3 | |
| Delmopinol SCHEMBL23705767 | 0.97 | PDK1 (0.33) | PDK1PDK2PDK3 | |
| Delmopinol SCHEMBL23705763 | 0.97 | PDK1 (0.33) | PDK1PDK2PDK3 | |
| SCHEMBL10474211 | 0.93 | PDK1 (0.32) | PDK1TSHR | |
| SCHEMBL10474877 | 0.91 | GBA2 (0.32) | PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2931050-A1 | BOTANICAL ANTIMICROBIAL COMPOSITIONS | The Trustees of Columbia University in the City of New York (US) | 2015-10-21 | — | — | EP | claimed |
| CN-104994878-A | Botanical antimicrobial compositions | UNIV COLUMBIA | 2015-10-21 | — | — | CN | claimed |
| US-8999365-B2 | Prevention of bacterial contamination | SINCLAIR PHARMACEUTICALS LIMITED (GB) | 2015-04-07 | — | — | US | claimed |
| WO-2014092999-A1 | BOTANICAL ANTIMICROBIAL COMPOSITIONS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-06-19 | — | — | WO | claimed |
| US-20080299052-A1 | Formulation to Prevent Plaque Formation | SINCLAIR PHARMACEUTICALS LIMITED (GB) | 2008-12-04 | — | — | US | claimed |
| CN-101175536-A | Formulation to prevent plaque formation | SINCLAIR PHARMACEUTICALS LTD (GB) | 2008-05-07 | — | — | CN | claimed |
| EP-1879662-A1 | FORMULATION TO PREVENT PLAQUE FORMATION | Sinclair Pharmaceuticals Limited (GB) | 2008-01-23 | — | — | EP | claimed |
| WO-2006120432-A1 | FORMULATION TO PREVENT PLAQUE FORMATION | SINCLAIR PHARMACEUTICALS LIMITED (GB) | 2006-11-16 | — | — | WO | claimed |
| US-12458584-B2 | Oral hygiene compositions for preventing the formation of oral biofilms and process for preparing the same | ISP INVESTMENTS LLC (US) | 2025-11-04 | — | — | US | disclosed |
| EP-3156057-B1 | DELMOPINOL-COATED ANIMAL CHEW FOR USE IN THE PREVENTION OR TREATMENT OF HALITOSIS | MAELOR LABORATORIES LTD (GB) | 2023-10-04 | — | — | EP | disclosed |
| US-11660300-B2 | Method of maintaining oral health in animals | Boehringer Ingelheim Animal Health USA Inc. | 2023-05-30 | — | — | US | disclosed |
| US-11578043-B2 | Salt of delmopinol | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2023-02-14 | — | — | US | disclosed |
| US-11384056-B2 | Method for the manufacturing of delmopinol intermediates | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2022-07-12 | — | — | US | disclosed |
| EP-3558952-B1 | METHOD FOR THE MANUFACTURING OF DELMOPINOL AND OF ITS INTERMEDIATES | LUNDBECK PHARMACEUTICALS ITALY S P A (IT) | 2022-02-09 | — | — | EP | disclosed |
| US-5147632-A | EDTA and derivatives, mouthwashes, toothpastes | WARNER-LAMBERT COMPANY (US) | 1992-09-15 | — | — | US | disclosed |
| WO-1992008442-A1 | IMPROVED ANTI-PLAQUE COMPOSITIONS COMPRISING A COMBINATION OF MORPHOLINOAMINO ALCOHOL AND ANTI-MICROBIAL AGENT | WARNER-LAMBERT COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008441-A1 | IMPROVED ANTI-PLAQUE COMPOSITIONS COMPRISING A COMBINATION OF MORPHOLINOAMINO ALCOHOL AND METAL SALTS | WARNER-LAMBERT COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992007549-A1 | IMPROVED ANTI-PLAQUE COMPOSITIONS COMPRISING A COMBINATION OF MORPHOLINOAMINO ALCOHOL AND ANTIBIOTIC | WARNER-LAMBERT COMPANY (US) | 1992-05-14 | — | — | WO | disclosed |
| WO-1992007548-A1 | IMPROVED ANTI-PLAQUE COMPOSITIONS COMPRISING A COMBINATION OF MORPHOLINOAMINO ALCOHOL AND CHELATING AGENT | WARNER-LAMBERT COMPANY (US) | 1992-05-14 | — | — | WO | disclosed |
| US-5085850-A | Bacterial destabilizing agent; tooth paste, mouth wash, chewing gum; non-staining | WARNER-LAMBERT COMPANY (US) | 1992-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12458584-B2 | Oral hygiene compositions for preventing the formation of oral biofilms and process for preparing the same | SMCHD1, TERB1, MLEC | PDK1 3518/4885TSHR 3572/4885PDK2 3401/4885 |
| US-11660300-B2 | Method of maintaining oral health in animals | O60361, MRM1, MSMO1 | PDK1 3914/4885TSHR 2666/4885PDK2 2781/4885 |
| US-11578043-B2 | Salt of delmopinol | DNM1L, MCOLN1, IMPA1 | PDK1 2598/4885TSHR 2774/4885PDK2 3485/4885 |
| US-11384056-B2 | Method for the manufacturing of delmopinol intermediates | THOP1, PTMS, CYP4A11 | PDK1 2573/4885TSHR 547/4885PDK2 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.